48results about How to "Enhance anti-cancer efficacy" patented technology

A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution.

The invention relates to a MRI (magnetic resonance imaging)-guided targeted photo-thermal agent and a preparation method of a chemotherapeutic system of the MRI-guided targeted photo-thermal agent. The method comprises the following steps: by using a hydrothermal method, preparing superparamagnetic ferroferric oxide nano-particles on PEI modified MoS2 in an in-situ preparation mode, thus obtaining a PEI modified MoS2 nano composite; preparing polyethylene glycol coupled targeting molecules by using EDC chemical; by using an EDC chemical, connecting polyethylene glycol with the targeting molecules to the PEI modified MoS2 nano composite in a covalent linkage mode; and through physical adsorption, loading a micromolecular anti-tumor drug on a carrier. The method disclosed by the invention is easy to operate and simple in step, and the prepared multi-functional MoS2 nano composite is good in biological compatibility, can be specifically gathered at tumor sites so as to effectively kill tumor cells, and can effectively integrate early diagnosis and late treatment so as to realize the integration of diagnosis and treatment of cancer treatment.

An emulsified injection for treating cancers is prepared from brucea fruit oil, medical emulsifier, isotonic agent and water through respectively dissolving oil phase and water phase, emulsifying and homogenizing.

The invention relates to the medicine field and discloses application of triptonide to anti-angiogenesis drugs. In-vitro and in-vivo tests for suppressing tumor neovascularization are carried out by adopting triptonide and the results show that the Chinese herbal medicine monomer triptonide can induce silencing of key genes for tumor neovascularization, promote tumor cell aging, differentiation and apoptosis, eliminate or reduce the neovascularization capacities of tumor cells, normalize and eliminate tumor vessels and improve the anticancer curative effects. Effective dose of triptonide and pharmaceutically acceptable auxiliary components can be used for preparing tablets, granules, capsules, suspension agents, syrup, emulsion or other common drug preparations. The drug preparations can be used for anti-angiogenesis. Besides, the extracts containing triptonide can be used for preparing the anti-angiogenesis drug preparations.

The invention relates to human body immunity improvement antifatigue health food and a preparation method thereof, and overcomes the technical problems of taking inconveniences and poor effects of the prior art, the human body immunity improvement antifatigue health food comprises the following components: by weight, 10-20 parts of cordyceps polysaccharides, 10-20 parts of ganoderma lucidum polysaccharides, 10-20 parts of spirulina, 5-15 parts of medlar and 1-3 parts of propolis, the invention also provides the preparation method thereof, and the preparation method can be widely used in the foodstuff preparation field.

The present invention provides methods for preventing, treating, and/or managing cancer, the method comprising administering to a subject in need thereof therapeutically effective amount of sodium meta arsenite that reduces or eliminates drug resistant cancer stem cell populations as well as drug resistant mature cancer cells.

The invention discloses a compound docetaxel ester microsphere injection and a preparation method thereof, belonging to the technical field of medicines. The compound docetaxel ester microsphere injection is characterized by being prepared from the following raw materials in weight parts: 0.5 to 5 parts of docetaxel, 30-150 parts of Brucea javanica oil, 30-150 parts of middle-chain triglyceride, 10-30 parts of lecithin, 10-60 parts of polyethylene glycol surface active agents, 20-35 parts of glycerine and 700-950 parts of sterilized water for injection. The compound docetaxel ester microsphere injection of the invention is oil in water type microsphere preparation. The docetaxel as a main drug is coated in the Brucea javanica and middle-chain triglyceride compound oil phase of the oil in water type microsphere. The microsphere has a smaller grain diameter (which is lower than 100nm), and the preparation has better stability. The compound oil phase compositions play a cooperative anticancer role, and reduce the stimulation reaction of the injection and the side reactions such as hemolysis, allergy and the like. The invention has targeting function and increases the medicine effect.

The invention discloses an isosorbide mononitrate derivative, a preparation method thereof and an application thereof to tumor combined treatment as shown in the formula (II). Ester is formed by isosorbide mononitrate and fatty acid through an esterification reaction, so that lipid solubility can be improved, and then a lipid nanoparticle passive targeting drug delivery system is further prepared. Afterwards, the drug combination is conducted by lipid nanoparticles of an isosorbide mononitrate fatty acid derivative and nano targeting anticancer drugs, and the therapeutic effect of chemotherapeutic drugs is improved.

It has been established that exposure to cytotoxic doses of HSP90 inhibitor is broadly immunosuppressive, whereas continuous exposure to low-dosages of the same inhibitor exerts anti-tumor activity. The anti-tumor activity is mediated by the host immune system. Compositions and methods for continuous, low-dose exposure to HSP90 inhibitors in combination with one or more immunostimulatory agents for the treatment of cancer are described. Typically, the HSP90 inhibitor is administered in an amount that is between 1% and 20% of the clinically-determined maximum tolerate dose. The immunostimulatory agent can be administered simultaneously with the HSP90 inhibitor, or at some time before or after the HSP90 inhibitor. Compositions including a sub-toxic dose of HSP90 inhibitor in combination with an immunostimulatory agent in an amount effective to treat cancer are also provided.

Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.

The invention provides a medicine composition for treating cancer. The medicine composition is prepared from the following raw material medicines in parts by weight: 6-21 parts of camptotheca acuminate fruit, 5-20 parts of taxus chinensis, 5-25 parts of glabrous sarcandra herb, 10-30 parts of polyporus umbellatus, 20-50 parts of astragalus membranaceus, 9-30 parts of curcuma zedoary, 9-24 parts of turtle shell, 9-30 parts of herba patriniae, 9-30 parts of radix ranunculi ternati, 10-30 parts of ligusticum wallichii and 10-30 parts of angelica sinensis. The medicine composition is efficient, low in toxicity and free of obvious side effects after being taken for a long time, can be used for treating various solid tumor cancers such as lung cancer, liver cancer, lymph cancer, breast cancer and cervical cancer, can effectively improve the survival rate of patients, and has a very good clinical application prospect.

The present invention relates to novel peptides, compositions and uses thereof useful in tissue permeabilization, in particular in the context of treatment of cancer prevention and/or treatment or induction of an immune response, in particular via mucosal vaccination or anti-opioid treatment.

The invention discloses a niraparib oral liquid and a preparation method thereof and belongs to the field of drug production. The niraparib oral liquid comprises the following components in parts by weight: 10-20 parts of niraparib, 4-8 parts of diazepam, 3-6 parts of malt selenium, 3-6 parts of vitamin E, 20-40 parts of filler, 3-6 parts of colza oil, 4-8 parts of acetone and 130-150 parts of deionized water. The preparation method comprises the following steps: respectively corresponding dissolving diazepam and vitamin E in acetone and colza oil; uniformly mixing niraparib, deionized water and a part of filler; adding the prepared diazepam solution and vitamin E solution; adding malt selenium and the remaining filler, uniformly mixing and then filling, instantly sterilizing and packing,thereby acquiring the niraparib oral liquid. The niraparib oral liquid disclosed by the invention is capable of boosting the niraparib to exert anticancer curative effect and reducing the adverse reactions thereof.

This document provides materials and methods for treating cancer (e.g., PD-L1⁺ cancers). For example, methods and materials for using compositions (e.g., compositions containing a small bioactive S249/T252 phospho-mimicking polypeptide of an RB polypeptide) to reduce PD-L1 expression within cancer cells are provided. In addition, methods and materials for using compositions (e.g., compositions containing a small bioactive S249/T252 phospho-mimicking polypeptide of an RB polypeptide) in combination with other cancer treatment methods or agents to increase the effectiveness exhibited against the cancer within a mammal (e.g., a human) are provided.